IP Library Granted Patent US 8,828,428
Granted Patent B1
US 8,828,428 · App. 14/254,545 · Granted Sep 9, 2014

Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same

Inventors: Robert E. Dudley (Rosemary Beach, FL); Panayiotis P. Constantinides (Gurnee, IL)
Assignee: Clarus Therapeutics, Inc.
A61K31/568A61K47/26A61K47/12A61K47/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,828,428
App. No.
14/254,545
Granted
Sep 9, 2014
Kind
B1
Abstract

A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.

Claims (4)

1. An oral pharmaceutical composition comprising (1) a testosterone ester chosen from testosterone enanthate; testosterone undecanoate; testosterone cypionate, and testosterone palmitate, (2) a lipophilic surfactant chosen from mono- and/or di-glycerides of fatty acids, (3) Cremophor RH40 (polyoxyl 40 hydrogenated castor oil), and (4) a polyethylene glycol with an average molecular weight of about 200 to about 10,000 g/mol, wherein said composition is free of ethanol.

2. The pharmaceutical composition of claim 1 wherein the testosterone ester is testosterone undecanoate.

3. The composition as recited in claim 1 wherein said mono and/or di-glycerides of fatty acids is chosen from Precirol ATO 5 (glyceryl palmitostearate) and Maisine (glyceryl mono-linoleate).

4. The composition as recited in claim 1 , wherein said composition contains 10% to 20% w/w of testosterone ester.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Dec 6, 2022
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS SUCCESSOR TO U.S. BANK NATIONAL ASSOCIATION
To: CLARUS THERAPEUTICS, INC.
Reel/Frame 062000/0052 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2022
From: CLARUS THERAPEUTICS, INC.
To: TOLMAR, INC.
Reel/Frame 061774/0516 →
SECURITY INTEREST Recorded Mar 12, 2020
From: CLARUS THERAPEUTICS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 052099/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2014
From: DUDLEY, ROBERT E; CONSTANTINIDES, PANAYIOTIS P
To: CLARUS THERAPEUTICS, INC.
Reel/Frame 033412/0188 →
Continuity (4)
Continuation 13553586 · Jul 19, 2012
Continuation 11911446
Provisional Application 60671454 · Apr 15, 2005
Provisional Application 60721971 · Sep 30, 2005